Cache Advisors LLC Invests $392,000 in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

Cache Advisors LLC bought a new stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 10,143 shares of the company's stock, valued at approximately $392,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Arrowstreet Capital Limited Partnership boosted its position in Protagonist Therapeutics by 36.7% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 216,069 shares of the company's stock valued at $8,340,000 after acquiring an additional 58,002 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its stake in Protagonist Therapeutics by 2.3% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 578,409 shares of the company's stock valued at $22,327,000 after acquiring an additional 12,906 shares during the period. Barclays PLC lifted its stake in Protagonist Therapeutics by 223.6% during the 3rd quarter. Barclays PLC now owns 126,995 shares of the company's stock valued at $5,714,000 after acquiring an additional 87,755 shares during the period. Louisiana State Employees Retirement System lifted its stake in Protagonist Therapeutics by 1.1% during the 4th quarter. Louisiana State Employees Retirement System now owns 28,800 shares of the company's stock valued at $1,112,000 after acquiring an additional 300 shares during the period. Finally, Pacer Advisors Inc. lifted its stake in Protagonist Therapeutics by 8.2% during the 4th quarter. Pacer Advisors Inc. now owns 1,876,466 shares of the company's stock valued at $72,432,000 after acquiring an additional 142,376 shares during the period. Hedge funds and other institutional investors own 98.63% of the company's stock.

Analyst Upgrades and Downgrades

PTGX has been the subject of several recent research reports. BTIG Research set a $73.00 target price on shares of Protagonist Therapeutics in a report on Monday, March 3rd. HC Wainwright reaffirmed a "buy" rating and set a $80.00 target price on shares of Protagonist Therapeutics in a report on Monday, May 19th. Truist Financial lifted their target price on shares of Protagonist Therapeutics from $60.00 to $76.00 and gave the company a "buy" rating in a report on Tuesday, March 11th. Wedbush reissued an "outperform" rating and issued a $70.00 price target on shares of Protagonist Therapeutics in a report on Friday, March 28th. Finally, The Goldman Sachs Group decreased their target price on Protagonist Therapeutics from $43.00 to $38.00 and set a "neutral" rating on the stock in a research report on Monday, February 24th. Two equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Protagonist Therapeutics presently has an average rating of "Moderate Buy" and an average target price of $65.44.

Insider Activity

In other Protagonist Therapeutics news, Director William D. Waddill sold 4,000 shares of the company's stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $54.25, for a total value of $217,000.00. Following the transaction, the director now owns 13,130 shares of the company's stock, valued at $712,302.50. This represents a 23.35% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CFO Asif Ali sold 24,903 shares of the company's stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $58.73, for a total transaction of $1,462,553.19. Following the completion of the transaction, the chief financial officer now directly owns 62,821 shares in the company, valued at $3,689,477.33. The trade was a 28.39% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 61,173 shares of company stock valued at $3,461,180. 4.90% of the stock is currently owned by insiders.

Protagonist Therapeutics Stock Performance

Shares of PTGX stock traded up $0.77 during trading hours on Tuesday, reaching $46.43. The company had a trading volume of 850,554 shares, compared to its average volume of 881,671. The stock has a fifty day moving average of $45.69 and a 200-day moving average of $42.53. The company has a market capitalization of $2.88 billion, a price-to-earnings ratio of 17.45 and a beta of 2.65. Protagonist Therapeutics, Inc. has a 12-month low of $27.00 and a 12-month high of $60.60.

Protagonist Therapeutics (NASDAQ:PTGX - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The company reported ($0.19) earnings per share for the quarter, beating the consensus estimate of ($0.50) by $0.31. The firm had revenue of $28.32 million for the quarter, compared to analysts' expectations of $30.44 million. Protagonist Therapeutics had a net margin of 52.76% and a return on equity of 34.68%. On average, analysts forecast that Protagonist Therapeutics, Inc. will post 2.43 EPS for the current year.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.